HDL Therapeutics
Vero Beach, US · Founded 2013 · Delaware corporation
HDL Therapeutics develops the PDS-2 System, an FDA-approved therapy that uses HDL ("good cholesterol") to regress plaques in the coronary arteries of patients with atherosclerosis and homozygous familial hypercholesterolemia (HoFH). The company operates in the pharmaceutical, biotechnology, and medical device space.
Founders & leadership
BB
Bryan BrewerDr. Brewer is the Chief Scientific Officer of the Issuer.
MM
Michael MatinExecutive
Reported raises · per SEC filings
Form D private placements$16.9M disclosed across 5 rounds · 2014–2023
▶$1.3MraisedJul 2023 · 15 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJul 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MatinExecutive Officer
- Gregg SessaDirector
- Dane AndreeffDirector
- Bryan BrewerExecutive Officer
- Offering amount
- $7M
- Amount sold
- $1.3M
- Proceeds to insiders
- $277K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedMar 2021 · 31 investors · BiotechnologyRule 506(b)
▶$3.4MraisedMar 2021 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dane AndreeffDirector
- Bryan BrewerExecutive Officer, Director
- Michael MatinExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $3.4M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedOct 2019 · 34 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2019 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MatinExecutive Officer, Director
- Dane AndreeffDirector
- Bryan BrewerExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedMay 2017 · 57 investors · BiotechnologyRule 506(b)
▶$7.2MraisedMay 2017 · 57 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bryan BrewerExecutive Officer, Director
- Michael MatinExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $7.2M
- Sales commissions
- $187.7K
- Proceeds to insiders
- $400K
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$2MraisedDec 2014 · 14 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2014 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MatinExecutive Officer, Director
- Bryan BrewerExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $2M
- Proceeds to insiders
- $500K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapLabcorp6 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Quest Diagnostics5 shared keywordsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
Medscape4 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with HDL Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does HDL Therapeutics do?
- HDL Therapeutics develops the PDS-2 System, an FDA-approved therapy that uses HDL ("good cholesterol") to regress plaques in the coronary arteries of patients with atherosclerosis and homozygous familial hypercholesterolemia (HoFH). The company operates in the pharmaceutical, biotechnology, and medical device space.
- How much funding has HDL Therapeutics raised?
- HDL Therapeutics has disclosed $16.9M raised across 5 rounds.
- Where is HDL Therapeutics headquartered?
- HDL Therapeutics is headquartered in Vero Beach, US.